KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gilead Sciences (GILD) EPS (Weighted Average and Diluted) (2016 - 2025)

Gilead Sciences (GILD) has disclosed EPS (Weighted Average and Diluted) for 17 consecutive years, with $1.75 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 23.24% year-over-year to $1.75, compared with a TTM value of $6.78 through Dec 2025, up 1732.43%, and an annual FY2025 reading of $6.78, up 1684.21% over the prior year.
  • EPS (Weighted Average and Diluted) was $1.75 for Q4 2025 at Gilead Sciences, down from $2.43 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $2.43 in Q3 2025 and bottomed at -$3.34 in Q1 2024.
  • Average EPS (Weighted Average and Diluted) over 5 years is $1.01, with a median of $1.25 recorded in 2021.
  • The sharpest move saw EPS (Weighted Average and Diluted) skyrocketed 3900.0% in 2023, then tumbled 517.5% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at $0.3 in 2021, then surged by 333.33% to $1.3 in 2022, then fell by 13.08% to $1.13 in 2023, then grew by 25.66% to $1.42 in 2024, then increased by 23.24% to $1.75 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for GILD at $1.75 in Q4 2025, $2.43 in Q3 2025, and $1.56 in Q2 2025.